Sector-Specific Global Patent Tactics: Technology-Pharmaceuticals-Manufacturing

There is no "one-size-fits-all" international patent strategy for commercial companies. The same patent roadmap might be right for a technology firm developing software, but insufficient or even flawed for a pharmaceutical company or heavy industry manufacturer. The reason is simple: each sector has a different R&D cycle, product lifecycle, regulatory intensity, counterfeiting profile, and commercialization method. Therefore, global patent tactics are shaped according to the sector.

Below, I explain how companies “adapt” their international patent strategy to the sector, along three main axes (technology/software-AI, pharmaceuticals-biotechnology, manufacturing-industry).

A) Global Patent Tactics for Technology/Software/AI Companies

1) Balance between "speed" and "coverage"

In the technology sector, because the product lifecycle is short, the patent process (application-examination-registration) often takes longer than the product's life cycle. Therefore, technology companies early application + priority protection in countries where fast registration is possible + PCT to save time .
However, the critical point here is that if the claims are weak when applying quickly, the patent will not stop the competitor. Therefore, technology companies generally:

a broad core set of requirements in the initial application,
Subsequently, it expands its portfolio through follow-up/improvement applications
.

2) Country differences in software/AI patentability

Software and AI-based inventions are more frequently rejected in some countries (particularly the US and, to some extent, other legal systems) for being considered "abstract ideas" or "computer programs." Conversely, under certain regimes, such as the European Patent Office (EPO), patentability for biotechnology or AI applications with a clear technical impact may be more favorable.
Company tactic:

In the US, strengthening the case with "technical impact + concrete implementation + system/method requirements",
To establish the technical problem and the technical contribution more clearly in Europe,
Differentiating country-based requirement sets.

3) Hunting for "white space" (patent gaps) and monitoring competitors

Because competition in the technology sector is so rapid, companies constantly monitor competitors' applications and look for patent gaps. This both determines the direction of R&D and provides the opportunity to "narrow/object to competitor patents before they grow.".

4) Hybrid protection: patent + trade secret

The training data, parameter optimizations, and model weights of AI models are often not easily extracted through reverse engineering. Therefore, while technology companies patent the core technical concept, they keep the performance-enhancing "fine-tuning" as trade secrets.

B) Global Patent Tactics for Pharmaceutical/Biotechnology Companies

In the pharmaceutical and biotechnology sectors, patents are not only a competitive advantage but also a financial justification for R&D investment. This is because clinical development costs are very high and risky; without patents, the return on this investment would not be sustainable.

1) A lifecycle and “patent families” focused strategy

Pharmaceutical companies don't settle for a single patent; they establish patent families to protect the product lifecycle .

core molecule/active ingredient patent,
Formulation, dosage, release system,
area of use (new indication),
production method,
combination therapies
. This is referred to in the literature as “strategic patenting” or life cycle extension tactics.

2) Regulation-patent synchronization

In pharmaceuticals, patent strategy is synchronized with licensing/clinical stages. Companies structure their patent applications around regulatory milestones such as marketing authorization, as data visibility increases when these milestones are reached.

3) Market choice: “early registration, strong enforcement”

Pharmaceutical and biotechnology companies generally:

large income markets (USA, EU, Japan, etc.),
countries with strong sanctions and high reparations regimes,
areas where the patentability of biotechnology is interpreted broadly
.

4) Biotechnology and platform technologies

Biotechnology companies patent not just single products, but entire platform technologies (e.g., gene editing, biological production processes). These patents are licensed to numerous product lines, becoming a global revenue engine. The commercialization of IP and the growth of licensing/patent monetization platforms in the biotech sector also demonstrate this importance.

C) Global Patent Tactics for Manufacturing/Industry/Machinery Companies

In manufacturing companies, patent strategy is generally the physical imitation of the product and control of the production chain .

1) Protection in countries of production (source-country patenting)

Industrial products can often be quickly copied through reverse engineering. Therefore, obtaining patents at the production/supply base prevents imitation at the "source." It also makes it more difficult for manufacturers in OEM/ODM relationships to resort to covert imitation production.

2) Product + process (method) dual protection

In industry, patenting not only the "product" but also the production method and process is becoming critical. This is because a competitor can circumvent the patent by claiming to produce the same product using a different method. Process patents close this loophole.

3) SEP approach in standard-dependent production

In fields such as automotive, telecommunications equipment, and energy infrastructure, where compliance with standards is mandatory, critical technical solutions included in these standards Standard-Essential Patents (SEPs) . Manufacturers with an SEP portfolio gain a strong position at the licensing table in the global market.

4) Geographical expansion is done according to "market order"

Manufacturing companies expand their patent portfolio in line with their export plans: first the main sales market, then strategic transit countries, and then secondary markets. Thus, patent costs are balanced by sales growth.

D) Common Point: Establishing the Right "Toolbox" According to the Sector

The common lesson of the three sectors is this:

Technology company: speed + country-specific patentability tactics + hybrid protection
Pharmaceutical/biotechnology company: life cycle + patent families + regulatory synchronization.
Manufacturing company: reverse engineering defense + country of origin protection + process patents

When a company establishes the right toolset for its sector, its patent strategy ceases to be a "general template" and becomes an integral part of its competitive model

Law Articles

Sector-Specific Global Patent Tactics: Technology-Pharmaceuticals-Manufacturing